Balanced news tone
News Sentiment
BCAB sentiment intelligence
Bioatla Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-8.8% over one week, -1.0% over four weeks, trend inactive, and below fair value.
BioAtla: BioAtla, Inc. - Reverse Split Option Symbol: BCAB New Symbol: BCAB1
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Executive pay, board and share data detailed in BioAtla (NASDAQ: BCAB) 10-K/A
BioAtla, Inc. filed an amended annual report (10-K/A) to include comprehensive details on executive compensation, board structure, and share ownership, which were previously omitted. The filing reflects a 50-for-1 share consolidation effective April 6, 2026, and provides updated
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 20:40
- Source
- Stock Titan
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
BioAtla to implement 50-for-1 share consolidation
This article announces that BioAtla will implement a 50-for-1 share consolidation. The content details this corporate action.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2026 02:39
- Source
- MSN
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
BCAB Stock Chart | BIOATLA INC (NASDAQ:BCAB)
This article provides a stock chart and real-time financial data for BIOATLA INC (NASDAQ:BCAB). It shows the current stock price, its daily change, and aftermarket activity. The page also lists various financial analysis tools and educational resources available on ChartMill.com.
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 18 Apr 2026 02:39
- Source
- ChartMill
BioAtla Announces 1-for-50 Reverse Stock Split Merger
BioAtla announced a 1-for-50 reverse stock split through a merger with its wholly owned subsidiary, effective April 6, 2026. This move is intended to consolidate the share base and potentially impact trading dynamics, while preserving the company's existing corporate identity. An
- Tone
- Negative 30/100
- Event
- Deals and strategy
- Published
- 12 Apr 2026 11:40
- Source
- The Globe and Mail
BioAtla Announces Share Consolidation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Mar 2026 07:00
- Source
- Market source
BioAtla shrinks share count 50-for-1 to meet Nasdaq's $1 bid rule
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Mar 2026 07:00
- Source
- Stock Titan
BioAtla announces 50-for-1 reverse stock split effective April 6
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Mar 2026 07:00
- Source
- Investing.com
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Biotech BioAtla to shed 70% of staff while weighing asset sales
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Mar 2026 08:00
- Source
- Stock Titan
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 02 Mar 2026 08:00
- Source
- Quiver Quantitative
BioAtla explores sale as it cuts 70% of workforce
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 02 Mar 2026 08:00
- Source
- Investing.com
BioAtla Faces Nasdaq Delisting Review
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Feb 2026 08:00
- Source
- TradingView
BioAtla to be suspended from Nasdaq after delisting determination
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Feb 2026 08:00
- Source
- Investing.com
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Nov 2025 08:00
- Source
- Investing News Network
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Nov 2025 08:00
- Source
- Investing News Network
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma Following Productive Type B Meeting with FDA
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 08 Sep 2025 07:00
- Source
- Investing News Network
Here's Why We're A Bit Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 21 Jul 2025 07:00
- Source
- simplywall.st
BioAtla (BCAB)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Dec 2020 18:43
- Source
- Zacks Investment Research
BioAtla (BCAB) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Dec 2020 00:13
- Source
- MarketBeat
Bioatla (BCAB) Stock News & Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Dec 2020 01:04
- Source
- Stock Titan